Skip to Main Content

Paper Details

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Blood
338
2018
ABL1, ABL1T315I, ALL, BCR, CML, CP-CML, Ph+ ALL, Philadelphia, Philadelphia chromosome, Philadelphia chromosome-positive leukemia, Ponatinib, abdominal pain, acute lymphoblastic leukemia, arterial occlusive events, chronic myeloid leukemia, constipation, dasatinib, dry skin, headache, nilotinib, patient, patients, ponatinib, rash, thrombocytopenia
Author NameAffiliation
Jorge CortesThe University of Texas MD Anderson Cancer Center
Dong Wook KimSeoul St. Mary's Hospital, Leukemia Research Institute, The Catholic University of Korea
Dong Wook KimSeoul St. Mary's Hospital, Leukemia Research Institute, The Catholic University of Korea
Moshe TalpazComprehensive Cancer Center, University of Michigan ann arbor
Daniel J DeAngeloDana-Farber Cancer Institute
Michael W DeiningerHuntsman Cancer Institute, University of Utah
Neil P ShahUniversity of California San Francisco
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
  • 1 - 8

Datasets

Release 1.2